Hosted on MSN1mon
Which San Diego startup landed the top deal of 2024? Hint: it’s not a biotech
In November, San Diego biotech Kate Therapeutics announced that it would be acquired by pharmaceutical giant Novartis for approximately $1 billion. The Kate acquisition was the third largest exit ...
Hosted on MSN3mon
Novartis buys gene therapy developer Kate for up to $1.1B
Novartis (NYSE:NVS) (OTCPK:NVSEF) announced Thursday the acquisition of Kate Therapeutics, a San Diego-based gene therapy developer, for up to $1.1B. According to the deal terms, the Swiss ...
pharmaphorum1d
Gene therapy firm Kate Tx snapped up by Novartis for $1.1bn
Novartis has reached an agreement to take control ... The Swiss pharma group said in a statement that the takeover of the San Diego-based startup will bolster its position in gene therapies ...
pharmaphorum2d
Novartis eyes year-end filing in US for Fabhalta in C3G
Novartis is cueing up a new indication in the ... Kidney Week congress in San Diego over the weekend – showed that Fabhalta (iptacopan) was able to achieve a sustained and significant reduction ...
Fierce Pharma10d
Roche touts head-to-head data for Xolair against oral immunotherapy for treating food allergies
A year after the FDA blessed Roche and Novartis’ Xolair (omalizumab) as the first medicine to reduce allergic reactions that can occur from accidental exposure to certain foods, the companies have ...